Psychedelics
EGF Theramed Raises $352,502 in First Tranche of Private Placement
EGF Theramed Health Corp. (CSE:TMED)(OTCQB:EVAHF) is pleased to announce that it has completed the first tranche of its previously announced (December 10, 2020) offering (the “Offering“), issuing 2,937,516 units (each a “Unit“) by way of non-brokered private placement at a price of $0.12 per Unit for gross proceeds of $352,502. Each Unit consists of one […]
Optimi Health Corp. (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has filed a preliminary prospectus (the “Preliminary Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Quebec, for an initial public offering of units of […]
Awakn Life Sciences announced today the selection of contract research organization (‘CRO’), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent (‘Harmful Use’) Alcohol Use Disorder (“AUD”). Awakn’s Phase IIb study will take place in the United Kingdom and […]
Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference
Mindset Pharma Inc. (CSE: MSET) (“Mindset“), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference “New Paradigms & Treatment Approaches in Mental Health”, being held February 3-4, 2021. James Lanthier, CEO of Mindset, […]
NEW WAVE HOLDINGS CORP. (“New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, is pleased to announce its launch of high quality new functional mushroom wellness collection under Way of Will Inc. WAY OF WILL Joins the ‘Shroom Boom’ with High Quality Functional Mushroom Wellness Collection Known […]
Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol
Toronto, Ontario–(Newsfile Corp. – January 14, 2021) – Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that it has completed the first step in identifying the medicinal potential of […]
TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license […]
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer See Official Release HereNEW YORK, Jan. 14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading […]
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Genetic Screening Test Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols Vancouver, BC – January 14, 2021 – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”) is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (“HaluGen”), a biotech company in the business of developing and commercializing […]
January 14, 2021 – Vancouver, BC: NeonMind Biosciences Inc. (CSE: NEON) (“NeonMind”) a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials […]
Mydecine Innovations : Announces C$10 Million Bought Deal Offering of Units
DENVER, Jan. 14, 2021 /CNW/ – Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord Genuity” or the “Underwriter”), pursuant […]
Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee
La Jolla, California–(Newsfile Corp. – January 14, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or the “Company“), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce the appointment of Gregory M. McKee to the Company’s board of directors. Mr. McKee brings more […]
Pure Extracts Delineates Study on Psilocybin Oral Tablets, Capsules and Nasal Gel
VANCOUVER, British Columbia, Jan. 14, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp . (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has delineated the timetable and milestones for its study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, […]
Novamind Expands Psychedelic Medicine Access in Utah
Enhanced clinic enables greater access to ketamine and Spravato™ treatment TORONTO, ON / ACCESSWIRE / January 13, 2021 / Novamind Inc. (CSE: NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, announces the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah (“Layton Clinic”), the largest clinic in the Company’s network. The redesigned Layton Clinic […]
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million. The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual […]
Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its plans to initiate another intellectual property strategy that will utilize its patented transmucosal thinstrip delivery method (“thinstrip delivery method”) in combination with its proprietary biosynthetic psilocybin, developed by its wholly-owned subsidiary, Vocan Biotechnologies Inc. (“Vocan”). The […]
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”or the “Company”) is pleased to announce the signing of a non-binding letter of intent (the “LOI“) for strategic investment and commercial cooperation with ATMA Journey Centers Inc. (“ATMA“), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing […]
NeonMind Announces Grants Pursuant to Stock Option Plan
NeonMind Biosciences Inc. (CSE: NEON)(“NeonMind“), a psychedelic drug development company, granted a total of 5,940,000 incentive stock options. 250,000 were granted to directors, 4,900,000 were granted to officers and 790,000 were granted to consultants under the Company’s incentive stock option plan (the “Plan“). The options are exercisable into common shares of the Company at a […]
NeonMind Biosciences Inc. (CSE: NEON)(“NeonMind“), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a […]
MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response. The study will provide an […]
PharmaDrug Announces LOI to Acquire Sairiyo Therapeutics Inc.
PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug“), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a binding letter of intent (the “LOI“), dated January 11, 2021, to acquire Sairiyo Therapeutics […]
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors. Additionally, Dean Ditto has joined […]
Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic therapeutics, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative technology, Kernel Flow (“Flow”), for its upcoming sponsored clinical work. Click here to view the accompanying film. Flow is a full-head […]
Champignon Brands Announces New CFO and New General Counsel
Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the Company’s appointment of Stephen R. Brooks as its new Chief Financial Officer and Peter Rizakos as the firm’s new General Counsel. These appointments complete the Company’s new top management team put into place by Dr. McIntyre […]
Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor. In his role, Mr. Keeney will work directly with the CEO of the Company, Timothy Ko, to develop multimedia […]
–Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced that it has appointed David E. Nichols, Ph.D., a renowned expert on the pharmacology and medicinal chemistry of psychedelics, as its Director of Molecular Pharmacology. He will collaborate closely with his son, Charles Nichols, Ph.D., the scientific […]
Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic therapeutics, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing November 15, 2020, as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “Transaction Agreement”) among […]
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
Silo Pharma to Receive Upfront Payment Combination of Cash and Preferred Stock Totaling One Million Dollars Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 […]
Psyched Wellnes Commences Antioxidant and Anti-Inflammatory Study on Muscimol
Psyched Wellness Ltd.(formerly Duncan Park Holdings Corporation) (CSE:PSYC, OTCQB:DCNPF,FRANKFURT:5U9) (“Psyched”) a life sciences company focused on the production and distribution of artisanal functional andpsychedelic mushrooms, is pleased to share that it has commenced a study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective modulation […]
Novamind Appoints Chuck Rifici to its Board of Directors
Novamind Inc. (CSE:NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, is pleased to update shareholders on the recent appointment of Chuck Rifici, a pioneer of the global cannabis industry, to the Company’s Board of Directors. Mr. Rifici joined Novamind’s Board in connection with the completion of the Company’s going public […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products.
Xtraction Services provides state-of-the-art, fully-automated, supercritical CO2 extraction machines with on-site staffing at no upfront cost, and a simple volume-based pricing model.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
